BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 36153645)

  • 21. ARHGAP9 inhibits colorectal cancer cell proliferation, invasion and EMT via targeting PI3K/AKT/mTOR signaling pathway.
    Sun J; Zhao X; Jiang H; Yang T; Li D; Yang X; Jia A; Ma Y; Qian Z
    Tissue Cell; 2022 Aug; 77():101817. PubMed ID: 35679685
    [TBL] [Abstract][Full Text] [Related]  

  • 22. IL-17F facilitates prostate cancer cell malignant phenotypes via activation of the PI3K/AKT signalling pathway.
    Zhu X; Zhao S; Ma X; Cao Z
    Andrologia; 2020 Nov; 52(10):e13750. PubMed ID: 32668495
    [TBL] [Abstract][Full Text] [Related]  

  • 23. HMGB1 Promotes Prostate Cancer Development and Metastasis by Interacting with Brahma-Related Gene 1 and Activating the Akt Signaling Pathway.
    Lv DJ; Song XL; Huang B; Yu YZ; Shu FP; Wang C; Chen H; Zhang HB; Zhao SC
    Theranostics; 2019; 9(18):5166-5182. PubMed ID: 31410208
    [No Abstract]   [Full Text] [Related]  

  • 24. Microrchidia family CW‑type zinc finger 2 promotes the proliferation, invasion, migration and epithelial‑mesenchymal transition of glioma by regulating PTEN/PI3K/AKT signaling via binding to N‑myc downstream regulated gene 1 promoter.
    Zhang J; Yang Y; Dong Y; Liu C
    Int J Mol Med; 2022 Feb; 49(2):. PubMed ID: 34913078
    [TBL] [Abstract][Full Text] [Related]  

  • 25. PSMA redirects cell survival signaling from the MAPK to the PI3K-AKT pathways to promote the progression of prostate cancer.
    Caromile LA; Dortche K; Rahman MM; Grant CL; Stoddard C; Ferrer FA; Shapiro LH
    Sci Signal; 2017 Mar; 10(470):. PubMed ID: 28292957
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Activation of PI3K-Akt signaling pathway promotes prostate cancer cell invasion.
    Shukla S; Maclennan GT; Hartman DJ; Fu P; Resnick MI; Gupta S
    Int J Cancer; 2007 Oct; 121(7):1424-32. PubMed ID: 17551921
    [TBL] [Abstract][Full Text] [Related]  

  • 27. METTL3-Mediated m
    Mao Y; Li W; Weng Y; Hua B; Gu X; Lu C; Xu B; Xu H; Wang Z
    Cell Transplant; 2022; 31():9636897221122997. PubMed ID: 36073002
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Exportin XPO7 acts as an oncogenic factor in prostate cancer via upregulation of TCF3.
    Lin Y; Zhan M; Xu B
    J Cancer Res Clin Oncol; 2023 Aug; 149(10):7663-7677. PubMed ID: 37000263
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The aryl hydrocarbon receptor ligand ITE inhibits cell proliferation and migration and enhances sensitivity to drug-resistance in hepatocellular carcinoma.
    Zhang X; He B; Chen E; Lu J; Wang J; Cao H; Li L
    J Cell Physiol; 2021 Jan; 236(1):178-192. PubMed ID: 32510618
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Beta-naphthoflavone (DB06732) mediates estrogen receptor-positive breast cancer cell cycle arrest through AhR-dependent regulation of PI3K/AKT and MAPK/ERK signaling.
    Wang C; Xu CX; Bu Y; Bottum KM; Tischkau SA
    Carcinogenesis; 2014 Mar; 35(3):703-13. PubMed ID: 24163404
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Knocking down FAM83B inhibits endometrial cancer cell proliferation and metastasis by silencing the PI3K/AKT/mTOR pathway.
    Lin Q; Chen H; Zhang M; Xiong H; Jiang Q
    Biomed Pharmacother; 2019 Jul; 115():108939. PubMed ID: 31079003
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Quercetin-6-C-β-D-glucopyranoside, natural analog of quercetin exhibits anti-prostate cancer activity by inhibiting Akt-mTOR pathway via aryl hydrocarbon receptor.
    Hamidullah ; Kumar R; Saini KS; Kumar A; Kumar S; Ramakrishna E; Maurya R; Konwar R; Chattopadhyay N
    Biochimie; 2015 Dec; 119():68-79. PubMed ID: 26476001
    [TBL] [Abstract][Full Text] [Related]  

  • 33. NLRC5 promotes cell migration and invasion by activating the PI3K/AKT signaling pathway in endometrial cancer.
    Fan Y; Dong Z; Shi Y; Sun S; Wei B; Zhan L
    J Int Med Res; 2020 May; 48(5):300060520925352. PubMed ID: 32431202
    [TBL] [Abstract][Full Text] [Related]  

  • 34. AIM2 inhibits the proliferation, invasion and migration, and promotes the apoptosis of osteosarcoma cells by inactivating the PI3K/AKT/mTOR signaling pathway.
    Zheng J; Liu C; Shi J; Wen K; Wang X
    Mol Med Rep; 2022 Feb; 25(2):. PubMed ID: 34913077
    [TBL] [Abstract][Full Text] [Related]  

  • 35. MIIP inhibits the growth of prostate cancer via interaction with PP1α and negative modulation of AKT signaling.
    Yan G; Ru Y; Yan F; Xiong X; Hu W; Pan T; Sun J; Zhang C; Wang Q; Li X
    Cell Commun Signal; 2019 May; 17(1):44. PubMed ID: 31092266
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Role of the PI3K/Akt pathway in cadmium induced malignant transformation of normal prostate epithelial cells.
    Kulkarni P; Dasgupta P; Bhat NS; Hashimoto Y; Saini S; Shahryari V; Yamamura S; Shiina M; Tanaka Y; Dahiya R; Majid S
    Toxicol Appl Pharmacol; 2020 Dec; 409():115308. PubMed ID: 33129824
    [TBL] [Abstract][Full Text] [Related]  

  • 37. GPCR48/LGR4 promotes tumorigenesis of prostate cancer via PI3K/Akt signaling pathway.
    Liang F; Yue J; Wang J; Zhang L; Fan R; Zhang H; Zhang Q
    Med Oncol; 2015 Mar; 32(3):49. PubMed ID: 25636507
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long noncoding RNA KB-1980E6.3 promotes breast cancer progression through the PI3K/AKT signalling pathway.
    He L; Tang L; Wang R; Liu L; Zhu P; Jiang K; Tu G
    Pathol Res Pract; 2022 Jun; 234():153891. PubMed ID: 35461041
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Aryl Hydrocarbon Receptor Promotes Cell Growth, Stemness Like Characteristics, and Metastasis in Human Ovarian Cancer via Activation of PI3K/Akt, β-Catenin, and Epithelial to Mesenchymal Transition Pathways.
    Therachiyil L; Krishnankutty R; Ahmad F; Mateo JM; Uddin S; Korashy HM
    Int J Mol Sci; 2022 Jun; 23(12):. PubMed ID: 35742838
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Scutellaria barbata D.Don (SBD) extracts suppressed tumor growth, metastasis and angiogenesis in Prostate cancer via PI3K/Akt pathway.
    Sheng D; Zhao B; Zhu W; Wang T; Peng Y
    BMC Complement Med Ther; 2022 May; 22(1):120. PubMed ID: 35505400
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.